Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | UBE2N | P61088 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424799 | 0.95 | CASP3 (0.79) | CASP3CYP1A2CYP2C19LMNAHPGD | |
| SCHEMBL13442861 | 0.93 | CASP3 (1.00) | CASP3CYP1A2CYP2C19LMNAHPGD | |
| SCHEMBL28737144 | 0.84 | UBE2N (0.81) | CASP3CYP1A2CYP2C19LMNAHPGD | |
| SCHEMBL11167209 | 0.84 | CASP3 (0.67) | CASP3HPGDADRA1DADRA1AADRA1B | |
| SCHEMBL326305 | 0.84 | CASP3 (0.85) | CASP3LMNAHPGDADRA1DADRA1A | |
| SCHEMBL30472950 | 0.84 | CASP3 (0.85) | CASP3LMNAHPGDADRA1DADRA1A | |
| SCHEMBL2643289 | 0.83 | CASP3 (0.63) | CASP3CYP1A2CYP2C19LMNAHPGD | |
| SCHEMBL18669018 | 0.83 | CASP3 (0.63) | CASP3CYP1A2CYP2C19HPGDUBE2N | |
| SCHEMBL8737445 | 0.82 | CASP3 (0.65) | CASP3HPGDADRA1DADRA1AADRA1B | |
| SCHEMBL18668950 | 0.82 | CES2 (0.67) | CASP3ADRA1DADRA1AADRA1BCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-23 | — | — | US | disclosed |
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-11-23 | — | — | US | disclosed |
| US-11731116-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-08-22 | — | — | US | disclosed |
| US-11731116-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-08-22 | — | — | US | disclosed |
| WO-2017137984-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017049409-A1 | COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME | THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2017-03-30 | — | — | WO | disclosed |
| CN-106432047-A | Synthesis method of astemizole drug intermediate N-(4-fluorobenzyl)phthalimide | 厦门市凯尔利信息科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106432047-A | Synthesis method of astemizole drug intermediate N-(4-fluorobenzyl)phthalimide | 厦门市凯尔利信息科技有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106008229-A | Synthesis method of astemizole drug intermediate p-fluorobenzylamine | 成都切斯特科技有限公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-105523989-A | Synthetic method of astemizole drug intermediate N-(4-fluorobenzyl)phthalimide | CHENGDU QIESITE TECH CO LTD | 2016-04-27 | — | — | CN | disclosed |
| CN-105523989-A | Synthetic method of astemizole drug intermediate N-(4-fluorobenzyl)phthalimide | CHENGDU QIESITE TECH CO LTD | 2016-04-27 | — | — | CN | disclosed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| EP-1960385-A1 | SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007053503-A1 | SUBSTITUTED DIHYDROISOINDOLONES AS ALLOSTERIC MODULATORS OF GLUCOKINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| EP-1419126-B1 | FLUOROUS NUCLEOPHILIC SUBSTITUTION OF ALCOHOLS AND REAGENTS FOR USE THEREIN | UNIV PITTSBURGH (US) | 2006-11-02 | — | — | EP | disclosed |
| US-6806357-B1 | REACTING THE ALCOHOL AND A NUCLEOPHILE WITH AN AZODICARBOXYLATE AND A PHOSPHINE. AT LEAST ONE OF THE AZODICARBOXYLATE AND THE PHOSPHINE INCLUDES AT LEAST ONE FLUOROUS TAG | UNIVERSITY OF PITTSBURGH | 2004-10-19 | — | — | US | disclosed |
| EP-1419126-A1 | FLUOROUS NUCLEOPHILIC SUBSTITUTION OF ALCOHOLS AND REAGENTS FOR USE THEREIN | UNIVERSITY OF PITTSBURGH (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003016246-A1 | FLUOROUS NUCLEOPHILIC SUBSTITUTION OF ALCOHOLS AND REAGENTS FOR USE THEREIN | UNIVERSITY OF PITTSBURGH (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372915-A1 | MANGANESE BASED COMPLEXES AND USES THEREOF FOR HOMOGENEOUS CATALYSIS | ADH1C, OTC, MLEC | CASP3 2636/4885CYP1A2 2604/4885CYP2C19 2590/4885 |
| US-20070099930-A1 | Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase | GCK, GCKR, GPR119 | CASP3 4136/4885CYP1A2 876/4885CYP2C19 1213/4885 |
| US-11731116-B2 | Manganese based complexes and uses thereof for homogeneous catalysis | ADH1C, OTC, ADH5 | CASP3 2530/4885CYP1A2 3168/4885CYP2C19 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.